Mylan enters MPP agreement over affordable hepatitis C generics

Mylan has entered into a sub-licensing agreement with the Medicines Patent Pool (MPP), a UN-backed public health organisation, to expand access to chronic hepatitis C medicines in developing countries. Under the agreement, announced yesterday, November 28, Mylan will produce and market a generic version of Bristol-Myers Squibb’s Daklinza (daclatasvir). The generic drug will be distributed in 112 low and middle income countries. Source: